Nifty
Sensex
:
:
13113.75
44618.04
4.70 (0.04%)
-37.40 (-0.08%)

Pharmaceuticals & Drugs - Global

Rating :
66/99

BSE: 500087 | NSE: CIPLA

758.35
02-Dec-2020
  • Open
  • High
  • Low
  • Previous Close
  •  758.00
  •  761.00
  •  751.15
  •  755.60
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  3983393
  •  30126.90
  •  829.05
  •  355.30

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 60,931.04
  • 33.11
  • 2
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 62,743.56
  • 0.53%
  • 3.57

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 36.70%
  • 5.90%
  • 16.12%
  • FII
  • DII
  • Others
  • 20.06%
  • 19.34%
  • 1.88%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 10.48
  • 4.73
  • 4.17

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 8.54
  • 4.61
  • 4.83

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 5.12
  • 3.04
  • 4.09

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 32.70
  • 34.09
  • 32.66

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 3.56
  • 3.31
  • 3.08

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 16.81
  • 16.30
  • 14.50

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Sep 20
Sep 19
Var%
Jun 20
Jun 19
Var%
Mar 20
Mar 19
Var%
Dec 19
Dec 18
Var%
Net Sales
5,038.29
4,395.78
14.62%
4,346.16
3,989.02
8.95%
4,376.19
4,403.98
-0.63%
4,371.00
4,007.54
9.07%
Expenses
3,861.72
3,486.28
10.77%
3,297.42
3,084.38
6.91%
3,742.67
3,442.93
8.71%
3,612.67
3,299.87
9.48%
EBITDA
1,176.57
909.50
29.36%
1,048.74
904.64
15.93%
633.52
961.05
-34.08%
758.33
707.67
7.16%
EBIDTM
23.35%
20.69%
24.13%
22.68%
14.01%
14.01%
17.35%
17.66%
Other Income
53.47
100.52
-46.81%
65.45
78.37
-16.49%
93.18
95.36
-2.29%
72.13
78.53
-8.15%
Interest
39.33
46.07
-14.63%
46.00
52.12
-11.74%
53.00
44.78
18.36%
46.17
44.19
4.48%
Depreciation
265.06
282.96
-6.33%
268.98
268.00
0.37%
345.80
510.28
-32.23%
277.89
293.13
-5.20%
PBT
925.65
680.99
35.93%
799.21
662.89
20.56%
327.90
501.35
-34.60%
506.40
448.88
12.81%
Tax
263.80
200.55
31.54%
227.78
192.24
18.49%
85.59
127.75
-33.00%
152.82
125.68
21.59%
PAT
661.85
480.44
37.76%
571.43
470.65
21.41%
242.31
373.60
-35.14%
353.58
323.20
9.40%
PATM
13.14%
10.93%
13.15%
11.80%
7.11%
7.11%
8.09%
8.06%
EPS
8.22
5.97
37.69%
7.10
5.85
21.37%
3.01
4.64
-35.13%
4.39
4.01
9.48%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Net Sales
18,131.64
17,131.99
16,362.41
15,155.71
14,394.29
13,594.89
11,345.44
10,173.39
8,279.33
7,020.71
6,323.84
Net Sales Growth
7.95%
4.70%
7.96%
5.29%
5.88%
19.83%
11.52%
22.88%
17.93%
11.02%
 
Cost Of Goods Sold
9,825.06
5,991.42
5,784.49
5,438.42
5,317.12
5,089.86
4,270.63
3,874.83
2,952.61
2,739.30
2,775.18
Gross Profit
8,306.58
11,140.57
10,577.92
9,717.29
9,077.17
8,505.03
7,074.81
6,298.56
5,326.72
4,281.41
3,548.66
GP Margin
45.81%
65.03%
64.65%
64.12%
63.06%
62.56%
62.36%
61.91%
64.34%
60.98%
56.12%
Total Expenditure
14,514.48
14,025.88
13,494.26
12,702.32
11,918.50
11,115.22
9,183.74
8,040.34
6,081.48
5,361.86
4,954.60
Power & Fuel Cost
-
327.43
335.11
298.82
251.73
245.92
228.28
218.63
233.12
235.35
198.55
% Of Sales
-
1.91%
2.05%
1.97%
1.75%
1.81%
2.01%
2.15%
2.82%
3.35%
3.14%
Employee Cost
-
3,027.01
2,856.53
2,690.10
2,633.82
2,434.01
1,967.72
1,542.96
1,036.02
772.50
565.59
% Of Sales
-
17.67%
17.46%
17.75%
18.30%
17.90%
17.34%
15.17%
12.51%
11.00%
8.94%
Manufacturing Exp.
-
1,372.03
1,284.94
1,220.67
1,192.77
1,596.79
737.11
644.42
541.58
583.18
627.94
% Of Sales
-
8.01%
7.85%
8.05%
8.29%
11.75%
6.50%
6.33%
6.54%
8.31%
9.93%
General & Admin Exp.
-
1,289.13
1,096.50
1,002.43
868.31
845.89
743.46
638.08
496.81
369.85
288.71
% Of Sales
-
7.52%
6.70%
6.61%
6.03%
6.22%
6.55%
6.27%
6.00%
5.27%
4.57%
Selling & Distn. Exp.
-
1,252.04
1,281.29
1,082.90
1,009.21
818.76
738.87
680.32
466.22
467.61
386.67
% Of Sales
-
7.31%
7.83%
7.15%
7.01%
6.02%
6.51%
6.69%
5.63%
6.66%
6.11%
Miscellaneous Exp.
-
766.82
855.40
968.98
645.54
83.99
497.67
441.10
355.12
194.07
386.67
% Of Sales
-
4.48%
5.23%
6.39%
4.48%
0.62%
4.39%
4.34%
4.29%
2.76%
1.77%
EBITDA
3,617.16
3,106.11
2,868.15
2,453.39
2,475.79
2,479.67
2,161.70
2,133.05
2,197.85
1,658.85
1,369.24
EBITDA Margin
19.95%
18.13%
17.53%
16.19%
17.20%
18.24%
19.05%
20.97%
26.55%
23.63%
21.65%
Other Income
284.23
369.38
476.57
357.65
228.69
208.21
165.55
265.37
222.14
139.52
91.68
Interest
184.50
197.36
168.43
114.23
159.38
206.63
168.29
145.74
33.91
38.34
25.10
Depreciation
1,157.73
1,099.95
1,097.15
949.83
1,322.93
754.22
504.71
372.64
330.48
312.22
273.33
PBT
2,559.16
2,178.18
2,079.14
1,746.98
1,222.17
1,727.03
1,654.25
1,880.04
2,055.60
1,447.81
1,162.49
Tax
729.99
631.20
569.53
250.11
179.76
331.59
400.03
463.38
544.31
306.51
195.22
Tax Rate
28.52%
28.98%
27.39%
14.98%
14.71%
19.20%
24.18%
24.65%
25.98%
21.17%
16.79%
PAT
1,829.17
1,593.98
1,544.87
1,413.31
1,013.38
1,372.01
1,206.07
1,400.73
1,551.06
1,141.30
967.27
PAT before Minority Interest
1,858.77
1,546.98
1,509.61
1,419.35
1,042.41
1,395.44
1,254.22
1,416.66
1,551.06
1,141.30
967.27
Minority Interest
29.60
47.00
35.26
-6.04
-29.03
-23.43
-48.15
-15.93
0.00
0.00
0.00
PAT Margin
10.09%
9.30%
9.44%
9.33%
7.04%
10.09%
10.63%
13.77%
18.73%
16.26%
15.30%
PAT Growth
11.00%
3.18%
9.31%
39.46%
-26.14%
13.76%
-13.90%
-9.69%
35.90%
17.99%
 
EPS
22.72
19.80
19.19
17.55
12.59
17.04
14.98
17.40
19.26
14.17
12.01

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Shareholder's Funds
15,763.00
15,012.28
14,229.19
12,543.66
11,516.22
10,801.49
10,050.35
9,018.68
7,638.93
6,666.13
Share Capital
161.25
161.14
161.02
160.90
160.68
160.59
160.58
160.58
160.58
160.58
Total Reserves
15,548.70
14,794.10
14,001.91
12,320.74
11,266.12
10,557.74
9,868.12
8,858.10
7,478.35
6,505.55
Non-Current Liabilities
2,972.37
4,646.15
4,259.05
4,514.99
1,407.13
2,417.66
2,028.05
1,024.96
824.27
697.34
Secured Loans
304.74
47.70
0.00
0.00
207.00
287.09
317.44
0.00
0.00
15.00
Unsecured Loans
2,064.54
3,782.37
3,662.11
3,645.36
14.88
22.19
0.43
0.55
3.25
2.92
Long Term Provisions
133.27
121.41
137.92
140.52
144.68
1,783.17
1,368.64
713.87
557.78
466.30
Current Liabilities
4,393.14
3,771.51
3,832.22
3,388.91
7,776.05
3,881.13
2,563.58
2,277.63
1,413.19
1,698.54
Trade Payables
2,281.81
1,947.99
2,119.12
1,586.30
1,475.82
1,452.06
979.53
828.36
691.77
720.88
Other Current Liabilities
706.65
541.86
647.04
908.95
1,006.14
654.55
408.67
250.89
489.93
235.28
Short Term Borrowings
447.15
486.16
435.87
467.23
4,969.67
1,392.48
910.47
966.38
10.20
523.06
Short Term Provisions
957.53
795.50
630.19
426.43
324.42
382.04
264.91
232.00
221.29
219.32
Total Liabilities
23,422.79
23,761.91
22,672.90
20,885.79
21,049.49
17,280.76
14,691.56
12,321.27
9,876.39
9,062.01
Net Block
9,558.59
9,546.51
9,949.14
9,508.16
9,368.32
6,829.64
6,496.47
3,609.97
3,215.49
3,094.18
Gross Block
15,009.61
13,790.31
12,960.01
11,370.70
10,167.62
9,561.55
8,676.27
5,317.52
4,626.35
4,240.55
Accumulated Depreciation
5,405.29
4,233.78
3,010.87
1,609.71
799.30
2,731.91
2,179.80
1,707.55
1,410.86
1,146.37
Non Current Assets
11,716.61
11,335.28
11,858.80
12,082.23
12,208.26
9,689.47
9,039.59
5,537.29
4,819.58
4,618.88
Capital Work in Progress
824.53
676.18
981.33
1,682.98
2,060.87
580.90
441.84
377.79
371.17
285.34
Non Current Investment
578.80
490.20
157.66
137.36
176.35
249.76
397.14
415.69
328.59
367.18
Long Term Loans & Adv.
670.59
455.57
514.96
543.67
426.18
1,860.78
1,552.40
978.96
865.38
841.20
Other Non Current Assets
84.10
166.82
255.71
210.06
176.54
168.39
151.74
154.88
38.95
30.98
Current Assets
11,706.18
12,426.63
10,814.10
8,803.56
8,841.23
7,591.29
5,651.97
6,783.98
5,056.81
4,443.13
Current Investments
1,016.52
2,125.79
1,102.21
837.39
582.34
390.02
311.43
2,116.75
940.52
223.59
Inventories
4,377.60
3,964.83
4,044.70
3,519.72
3,808.05
3,780.62
2,895.26
2,387.07
1,850.08
1,906.16
Sundry Debtors
3,891.31
4,150.72
3,102.45
2,582.17
2,356.27
1,997.72
1,638.89
1,668.84
1,553.58
1,490.82
Cash & Bank
1,003.91
618.81
965.61
638.27
871.40
564.26
175.76
143.01
90.46
95.97
Other Current Assets
1,416.84
415.53
480.20
418.17
1,223.17
858.67
630.63
468.31
622.17
726.59
Short Term Loans & Adv.
974.82
1,150.95
1,118.93
807.84
786.12
713.07
595.13
463.21
459.94
533.77
Net Current Assets
7,313.04
8,655.12
6,981.88
5,414.65
1,065.18
3,710.16
3,088.39
4,506.35
3,643.62
2,744.59
Total Assets
23,422.79
23,761.91
22,672.90
20,885.79
21,049.49
17,280.76
14,691.56
12,321.27
9,876.39
9,062.01

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Cash From Operating Activity
3,068.45
1,691.14
1,462.76
2,381.76
1,740.81
1,173.43
1,563.31
1,397.67
1,712.76
1,025.10
PBT
2,178.18
2,079.14
1,669.46
1,222.17
1,727.03
1,654.25
1,880.04
2,095.38
1,447.81
1,162.49
Adjustment
1,365.53
1,268.77
1,293.82
1,374.42
950.85
630.05
552.80
283.82
396.66
288.84
Changes in Working Capital
372.99
-1,063.54
-778.48
235.44
-429.38
-718.61
-561.26
-519.84
199.76
-162.03
Cash after chg. in Working capital
3,916.70
2,284.37
2,184.80
2,832.03
2,248.50
1,565.69
1,871.58
1,859.36
2,044.23
1,289.30
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-848.25
-593.23
-722.04
-450.27
-507.69
-392.26
-308.27
-461.69
-331.47
-264.20
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
104.04
-1,668.68
-854.01
-1,310.21
-4,522.63
-941.15
-1,249.86
-2,062.89
-965.10
-908.39
Net Fixed Assets
-489.16
-173.16
-509.84
-889.04
1,487.25
-534.38
-437.26
-692.52
-460.09
-601.86
Net Investments
-1,439.15
-1,239.74
-351.09
-30.10
164.99
-833.97
-985.31
-1,566.67
-464.50
-305.55
Others
2,032.35
-255.78
6.92
-391.07
-6,174.87
427.20
172.71
196.30
-40.51
-0.98
Cash from Financing Activity
-2,948.82
-348.72
-385.48
-1,325.68
3,104.06
164.78
-265.63
717.77
-753.17
-82.80
Net Cash Inflow / Outflow
223.67
-326.26
223.27
-254.13
322.24
397.06
47.82
52.55
-5.51
33.91
Opening Cash & Equivalents
508.36
853.47
610.35
858.15
545.84
175.76
143.01
90.46
95.97
62.06
Closing Cash & Equivalent
742.38
508.36
853.46
610.35
858.15
564.26
175.76
143.01
90.46
95.97

Financial Ratios

Consolidated /

Standalone
Description
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Book Value (Rs.)
194.85
185.62
175.92
155.15
142.23
133.38
124.79
112.21
95.03
82.91
ROA
6.56%
6.50%
6.52%
4.97%
7.28%
7.85%
10.49%
13.97%
12.05%
10.94%
ROE
10.09%
10.37%
10.65%
8.72%
12.61%
12.10%
14.89%
18.64%
15.98%
15.40%
ROCE
12.53%
11.94%
10.20%
8.28%
13.24%
15.33%
19.05%
24.15%
19.96%
18.08%
Fixed Asset Turnover
1.88
1.79
1.25
1.36
1.40
1.26
1.47
1.69
1.61
1.79
Receivable days
54.10
55.36
68.17
61.60
57.62
57.94
58.66
70.11
77.94
87.29
Inventory Days
56.12
61.13
90.71
91.41
100.43
106.36
93.68
92.19
96.16
97.61
Payable days
57.55
59.02
57.37
46.96
48.81
52.17
44.93
48.58
50.51
56.11
Cash Conversion Cycle
52.66
57.47
101.50
106.05
109.24
112.14
107.41
113.72
123.59
128.78
Total Debt/Equity
0.18
0.29
0.29
0.33
0.46
0.16
0.12
0.11
0.00
0.09
Interest Cover
12.04
13.34
15.61
8.67
9.36
10.83
13.90
62.79
38.76
47.31

News Update:


  • Cipla signs licensing agreement with Multi G
    18th Nov 2020, 09:25 AM

    This licencing agreement is part of Cipla’s efforts to enhance global access to life- saving treatments and diagnostic infrastructure for patients in need

    Read More
  • Cipla looking at sustaining growth through pandemic
    9th Nov 2020, 09:26 AM

    The drug firm has earmarked digital adoption and resilient operations as first of the key priorities for the coming quarters to achieve sustained growth

    Read More
  • Cipla reports 41% rise in Q2 consolidated net profit
    7th Nov 2020, 10:45 AM

    Total consolidated income of the company increased by 13.24% at Rs 5091.76 crore for Q2FY21

    Read More
  • Cipla - Quarterly Results
    6th Nov 2020, 18:15 PM

    Read More
  • Cipla launches antibody detection kits for COVID-19 in India
    29th Oct 2020, 09:12 AM

    The company's distribution network will help in ensuring the seamless supply of kits across the country

    Read More
  • Cipla launches generic Nintedanib for treatment of IPF
    20th Oct 2020, 16:49 PM

    This launch marks yet another milestone in Cipla’s decade-long commitment to treat IPF, a rare lung disease that impacts ten in one lakh people

    Read More
  • Cipla’s US arm gets complete response letter from USFDA for IV Tramadol
    13th Oct 2020, 10:17 AM

    The FDA requires an adequate terminal sterilization validation prior to NDA approval, which is planned for later this quarter

    Read More
  • Cipla gets USFDA’s final approval for Dimethyl Fumarate DR Capsules
    25th Sep 2020, 09:24 AM

    The product is available for shipping immediately

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.